SCHEMBL23055181

SCHEMBL23055181

CC(C)(C)Cc1ccc(Cl)cc1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
HIF1A Q16665 4/20 0.45
HPGD P15428 4/20 0.45
ALOX15 P16050 4/20 0.45
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
USP2 O75604 2/20 0.45
CASP1 P29466 2/20 0.45
ALOX12 P18054 2/20 0.45
HSP90AA1 P07900 2/20 0.45
IDO1 P14902 2/20 0.45
HTT P42858 2/20 0.45
SLC22A1 O15245 1/20 0.45
LMNA P02545 1/20 0.45
HSPD1 P10809 1/20 0.45
HSPA5 P11021 1/20 0.45
BLM P54132 1/20 0.45
HSPE1 P61604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9917350 0.80 HTR2A (0.39) CYP3A4MEN1KMT2AIDO1ALDH1A1
SCHEMBL6886022 0.79 GGPS1 (0.55) CYP3A4MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL10026839 0.79 TYR (0.58) CYP3A4MEN1KMT2AALOX15MAPT
SCHEMBL5376298 0.78 ESR1 (0.54) CYP3A4MEN1KMT2AHPGDALOX15
SCHEMBL15107551 0.78 CA3 (0.52) MEN1KMT2AESR1ANO1
SCHEMBL12791096 0.78 MEN1 (0.42) CYP3A4MEN1KMT2AHIF1AHPGD
SCHEMBL9917352 0.78 CYP3A4 (0.39) CYP3A4MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL13508517 0.78 TRPA1 (0.48) MEN1KMT2AHPGDALOX15MAPT
SCHEMBL16576628 0.77 GGPS1 (0.38) CYP3A4MEN1KMT2AHIF1AHPGD
SCHEMBL1005910 0.77 HSD17B10 (0.50) CYP3A4MEN1KMT2AHIF1AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators SYNGENE INTERNATIONAL LIMITED (IN) 2023-02-21 US disclosed
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators DGKZ, DGKA, DGKG CYP3A4 4142/4885MEN1 2784/4885KMT2A 2162/4885
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG CYP3A4 4142/4885MEN1 2784/4885KMT2A 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.